Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients.
Kenny LM, Coombes RC, Oulie I, Contractor KB, Miller M, Spinks TJ, McParland B, Cohen PS, Hui AM, Palmieri C, Osman S, Glaser M, Turton D, Al-Nahhas A, Aboagye EO.
Kenny LM, et al.
J Nucl Med. 2008 Jun;49(6):879-86. doi: 10.2967/jnumed.107.049452. Epub 2008 May 15.
J Nucl Med. 2008.
PMID: 18483090
Free article.
Clinical Trial.